ClinicalTrials.gg
RecruitingNCT06645470M3Updated May 11, 2026

Muscle and Movement With Anti-Obesity Medications

An interventional study of Standard Medical Care (SMC) and Monitoring Contacts in Obesity and Overweight, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Obesity by University of Kansas Medical Center — 9 open to participants now, 9 under way, none of them phase 3. Obesity · University of Kansas Medical Center.

Planned enrollment
17th of 29
40 · median 60
Started
2024
with 4 others
No phase
28 of 32
6 open now
Registered
29th of 32
by date

Among the 32 studies in Obesity by University of Kansas Medical Center, this one is the 17th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2024, is one of 28 with no phase, and was the 29th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 32 studies in Obesity by University of Kansas Medical Center are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Obesity by University of Kansas Medical Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about changes in body composition related to obesity medication use, and whether aerobic or resistance exercise training will impact these body composition changes. It will also provide information about whether aerobic or resistance exercise training has additional benefits on other health and fitness measurements. The main questions it aims to answer are:

  • Is there a difference in the change in body composition (fat mass, lean mass, muscle mass, and bone content) between the standard medical care and the exercise conditions (aerobic training and resistance training)?
  • Is there a difference in the change in body weight and BMI between the standard medical care and the exercise conditions (aerobic training and resistance training)?
  • Is there a difference in the change in cardiorespiratory fitness between the standard medical care and the exercise conditions (aerobic training and resistance training)?
  • Is there a difference in how much physical activity is completed between the standard medical care and the exercise conditions (aerobic training and resistance training)?
  • Is there a difference in the change in physical function between the standard medical care and the exercise conditions (aerobic training and resistance training)?
  • Is there a difference in the change in muscle strength between the standard medical care and the exercise conditions (aerobic training and resistance training)?
  • Is there a difference in the change in resting blood pressure between the standard medical care and the exercise conditions (aerobic training and resistance training)?
  • Is there a difference in the change in food intake between the standard medical care and the exercise conditions (aerobic training and resistance training)?
  • Is there a difference in the change in health-related quality of life between the standard medical care and the exercise conditions (aerobic training and resistance training)?

Participants will:

  • Participate in an intervention for a period of 6 months that involves being assigned to a no exercise/standard medical care condition, or a supervised exercise condition (aerobic training or resistance training).
  • Visit the clinical before starting the study and at 6 months to complete study measurements of their body composition and other measurements to monitor their progress.
  • Complete a brief monitoring session at weeks 6, 12, and 18 across the 6 months.
  • Complete supervised exercise sessions at the research center 3x per week for 6 months (Participants in the exercise groups only: aerobic training or resistance training).
03

Conditions studied

  • Obesity and Overweight

Keywords

  • exercise
  • weight loss
  • obesity medication
  • obesity
  • overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both males and females of all race/ethnic groups are eligible for participation in this study.
  • Age: Randomized Study: Adults that are 18 to \<60 years of age. Observational Study: Adults that are >60 years of age.
  • Newly prescribed AOM (semaglutide, tirzepatide) for the treatment of obesity, approval for treatment (pharmacy, insurance, etc.), and the participant agreeing to start this treatment and continue treatment for at least 6 months (the participant will be recruited prior to this medication being initiated).
  • (BMI) of >27.0 kg/m2 with at least one weight-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) provided it this does not compromise the ability to safely complete the screening or outcome measures or to engage in the prescribed exercise interventions), or >30 kg/m2 without weight-related complications. Enrollment will not be limited based on an upper BMI level provided that the participant meets the other eligibility requirements. However, weight or size limits of the dual-energy x-ray absorptiometry (DXA) system that is used to assess body composition must not be exceeded.
  • Ability to provide prior to participation in this study.
  • Clearance from the study physician for meeting all eligibility criteria for this study.

Exclusion criteria

Exclusion Criteria:

  • Type 2 diabetes.
  • Report moderate-to-vigorous exercise for >60 min/week, and >1 day of structured cardiovascular or resistance exercise over the past 3 months.
  • Report sustained weight loss of >3% in the past 3 months.
  • History of metabolic/bariatric surgery.
  • Females who are pregnant, pregnant within the past 6 months, or reporting a planned pregnancy during the study period.
  • Report a current medical condition or treatment for a medical condition that could affect body weight or contradict engagement in any aspect of the outcome measures or interventions.
  • History of muscle conditions that may impact the quality of muscle or response to the study interventions (e.g., myopathy, muscular dystrophy, rhabdomyolysis, etc.).
  • Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction or history of cardiomyopathy, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).
  • Resting systolic blood pressure of >160 mmHg or resting diastolic blood pressure of >100 mmHg. If medicated for blood pressure control, the medication dose needs to be stable for >6 months.
  • Eating disorders that would contraindicate weight loss or physical activity.
  • Alcohol or substance abuse.
  • Current psychological condition that is untreated, hospitalization for a psychological condition within the past 12 months, or not being on a stable dose of treatment for at least 6 months.
  • Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance at scheduled intervention sessions or assessments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Standard Medical Care

    Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study and will also receive brief contacts from the research staff at weeks 6, 12, and 18.

    Other: Standard Medical Care (SMC) · Behavioral: Monitoring Contacts · Other: Nutrition Education

  • Experimental
    Standard Medical Care plus Aerobic Training

    Standard Medical Care plus Aerobic Training will continue to receive their regular standard clinical care during the 6-month intervention period of this study and will also receive supervised aerobic exercise in addition to brief contacts from the research staff at weeks 6, 12, and 18.

    Other: Standard Medical Care (SMC) · Behavioral: Monitoring Contacts · Behavioral: Aerobic Training · Other: Nutrition Education

  • Experimental
    Standard Medical Care plus Resistance Training

    Standard Medical Care plus Resistance Training will continue to receive their regular standard clinical care during the 6-month intervention period of this study and will also receive supervised resistance exercise in addition to brief contacts from the research staff at weeks 6, 12, and 18.

    Other: Standard Medical Care (SMC) · Behavioral: Monitoring Contacts · Behavioral: Resistance Training · Other: Nutrition Education

Interventions

  • OtherStandard Medical Care (SMC)

    Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study.

  • BehavioralMonitoring Contacts

    Participants will receive contacts with the research staff at weeks 6, 12, and 18.

  • BehavioralAerobic Training

    Aerobic Training will be supervised exercise. It will occur on 3 days per week and will progress to 50 minutes per session (150 minutes per week). The intensity of the exercise will progress from 60%±5% to 70%±5% of age-predicted maximal heart rate (if taking beta-blocker medication intensity will progress from a Rating of Perceived Exertion of 11-13 to 12-14 based on the 6-20 Borg scale). While walking will be the preferred mode of exercise, alternative forms of cardiovascular exercise (upright cycling, elliptical, etc.) are allowed to accommodate any physical limitations that may be present for a participant. Heart rate will be monitored throughout these exercise sessions.

  • BehavioralResistance Training

    Resistance Training will be supervised exercise. It will occur 3 days per week and includes 8 exercises performed in a prespecified order. Week 1-2 sessions focus on familiarization to acclimate the participant to the equipment, proper form, to establish initial weight (load) for training, and with performing multiple sets per day. For Weeks 3-8, participants will engage in 2 sets per exercise with the weight adjusted to elicit muscle fatigue in 8-12 repetitions per set. This progresses to 3 sets per exercise from Week 9 until the end of the intervention period. When 12 repetitions for a specific exercise can be achieved, the resistance will increase for that exercise at the next session. There is a 90 second rest period between each set of an exercise. Heart rate will be monitored throughout these exercise sessions.

  • OtherNutrition Education

    A single counseling session to discuss the dietary recommendations when taking an obesity medication.

06

What researchers measure

Primary outcomes

  1. Lean Body Mass

    Lean body mass (kg) will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

Secondary outcomes

  1. Body Fat Mass

    Body fat mass (kg) will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

  2. Percent Body Fat

    Percent body fat will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).

    Time frame: 0 and 6 months

  3. Body Weight

    Body weight will be assessed in duplicate using a calibrated digital scale to the nearest 0.1 kg.

    Time frame: 0 and 6 months; 6, 12, 18 weeks

  4. Body Height

    Body height will be assessed in duplicate using a wall mounted stadiometer to the nearest 0.1 cm.

    Time frame: 0 and 6 months; 6, 12, and 18 weeks

  5. Body Mass Index

    Measurements of weight and height will be used to compute BMI (kg/m2).

    Time frame: 0 and 6 months; 6, 12, 18 weeks

  6. Bone Mineral Content

    Bone mineral content (grams) will be assessed using a total body scan from dual-energy x-ray absorptiometry (DXA).

    Time frame: o and 6 months

  7. Muscle Mass

    Muscle mass will be assessed using the deuterated creatine (D3Cr) dilution method. A 30mg capsule of D3Cr is ingested and 48-72 hrs later, a fasting urine sample is provided for analysis.

    Time frame: 0 and 6 months

  8. Muscular Strength

    Muscular strength will be assessed using isometric leg extension on a Biodex.

    Time frame: 0 and 6 months

  9. Muscular Strength

    Muscular strength will be assessed using grip strength with a hand grip dynamometer.

    Time frame: 0 and 6 months

  10. Physical Function

    Physical Function will be assessed using the Short Physical Performance Battery (SPPB) that includes balance, gait speed, and chair stands. A composite score with a range from 0 to 12 (no units) of these measures is used. A higher score represents better physical functioning.

    Time frame: 0 and 6 months

  11. Cardiorespiratory Fitness

    Cardiorespiratory fitness will be represented as milliliters of oxygen consumed per kilogram of body weight per minute (ml/kg/min) measured with a metabolic cart during a submaximal graded exercise test that is terminated when the participant achieves 85% of age-predicted maximal heart rate.

    Time frame: 0 and 6 months

  12. Cardiorespiratory Fitness

    Cardiorespiratory fitness will be represented as total liters of oxygen consumed per minute (L/min) measured with a metabolic cart during a submaximal graded exercise test that is terminated when the participant achieves 85% of age-predicted maximal heart rate.

    Time frame: 0 and 6 months

  13. Cardiorespiratory Fitness

    Cardiorespiratory fitness will be the duration measured in minutes to achieve 85% of age-predicted maximal heart rate during a submaximal graded exercise test performed on a treadmill.

    Time frame: 0 and 6 months

  14. Resting Blood Pressure

    Resting seated blood pressure, both systolic and diastolic (mmHg), will be assessed using an automated system.

    Time frame: 0 and 6 months; 6, 12, and 18 weeks

  15. Energy Intake (Dietary Intake)

    Energy Intake (Dietary Intake) expressed as kilocalories eaten per day (kcal/day) will be measured using the Diet History Questionnaire (DHQ) developed by NCI. A higher score represents more calories eaten.

    Time frame: 0 and 6 months

  16. Physical Activity

    Physical activity is measured by the Global Physical Activity Questionnaire (GPAQ). This assesses time spent in recreational, occupational, household, and transportation physical activities and is represented as minutes per week. Higher minutes per week indicate greater physical activity participation. The range is 0 to 10,080 minutes per week.

    Time frame: 0 and 6 months

  17. Health-Related Quality of Life

    Health-Related Quality of Life will be measured with a 36-item questionnaire (RAND 36-Item Health Survey) that includes 8 subscales of vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health or emotional wellbeing. All items are scored so that a high score defines a more favorable health state. The range of the final score for each subscale is 0-100.

    Time frame: 0 and 6 months

Other outcomes

  1. Demographic Characteristics

    Demographic Characteristics will be assessed using a survey.

    Time frame: 0 months

  2. Lifestyle and Health History

    A questionnaire developed specifically for this study that is conducted as an interview will be used to assess lifestyle and health factors to describe the sample for this study. The score is either "yes" or "no" identifying the presences of a lifestyle or health factor.

    Time frame: 0 months

  3. Medication History

    A questionnaire developed specifically for this study will be used to assessment medication history. The data collected include the type of medication, dose of medication, and frequency that the medication is taken, and what condition the medication is indicated to treat.

    Time frame: 0 and 6 months; 6, 12, and 18 weeks

  4. Adverse and Serious Adverse Events

    Participants will be queried using a survey developed specifically for this study will be used to assess for adverse events and serious adverse events.

    Time frame: 0 and 6 months; 6, 12, and 18 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Jakicic JM, Rogers RJ. The Role of Exercise in the Contemporary Era of Obesity Management Medications. Curr Sports Med Rep. 2025 Aug 1;24(8):240-245. doi: 10.1249/JSR.0000000000001272. PubMed 40758789 ↗

Individual participant data

Plan to share: Yes — The summary data for each of the study outcomes and other additional demographic characteristics will be made available. The Study Protocol (which includes the statistical analysis plan), Manual of Procedures, Data Collection Forms, and a Data Dictionary to explain the data variables will be provided.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: The data will be made available no later than the time of an associated publication of study outcomes or at the end of the performance period, whichever comes first. The data provided to the repository will be available indefinitely while that repository continues to exist.

Access criteria: The information included with the IPD will be made available to appropriate individuals only after the requester confirms their willingness to comply with an appropriate "Data Use Agreement" that complies with NIH policies, the policies of the institution where the study has been conducted, and the elements of informed consent.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2026, 21 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 21 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 16, 2024
StartActual
Dec 1, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06645470
Responsible party
Renee Rogers (Senior Scientist, University of Kansas Medical Center) — Principal investigator
First posted
Oct 16, 2024
Start date
Dec 1, 2024
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
May 11, 2026

Study contacts

Renee J. Rogers, Ph.D.
Contact
rrogers10@kumc.edu
913-588-8580
John M. Jakicic, Ph.D.
Contact
jjakicic@kumc.edu
913-588-9078
Renee J. Rogers, Ph.D.
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion